Seborrheic Keratosis News and Research

RSS

Avoiding the cause of actinic keratosis is key for the prevention of the skin condition. The primary cause of the condition is ultraviolet (UV) radiation from sunlight and sun protection is, therefore, essential in the prevention of the skin condition.

Novel skin imaging technology improves the accuracy of basal cell carcinoma diagnosis

A novel imaging technique significantly improves the accuracy of the diagnosis of basal cell carcinoma (BCC) – the most frequent skin cancer – compared to clinical and dermoscopic examinations alone, according to new research being presented at the 31st European Academy of Dermatology and Venereology Congress.

7 Sep 2022

Topical solution may be less cytotoxic than cryosurgery for patients with seborrheic keratosis

Seborrheic keratosis is the most common noncancerous skin growth in adults seen by doctors in everyday practice.

29 Mar 2018

Eclipse Aesthetics partners with Skincential Sciences to distribute Clearista product line

Eclipse Aesthetics, LLC has formed a partnership with Skincential Sciences, a medical diagnostics company in southern California. Eclipse will serve as the exclusive distributor for ClearistaPRO, specially formulated products to safely and effectively remove biomarkers from tissue.

13 Mar 2016

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK), one of the most common types of skin tumors.

1 Jul 2014

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.

21 Jan 2014

Seborrheic Keratosis News and Research

Further Reading

Novel skin imaging technology improves the accuracy of basal cell carcinoma diagnosis

Topical solution may be less cytotoxic than cryosurgery for patients with seborrheic keratosis

Eclipse Aesthetics partners with Skincential Sciences to distribute Clearista product line

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News